Goodwin Procter advised HIBio on the deal while Orrick represented MorphoSys.HIBio announced its equity participation agreement and license agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR). Under…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
